10x Genomics (TXG) News Today $15.08 -0.01 (-0.07%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Avanza Fonder AB Makes New $945,000 Investment in 10x Genomics, Inc. (NASDAQ:TXG)Avanza Fonder AB purchased a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 65,816 shares of the company's stock, valued at approximately $945,000. AJanuary 20 at 3:43 AM | marketbeat.comWeiss Ratings Reaffirms Sell (E+) Rating for 10x Genomics (NASDAQ:TXG)Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday.January 19 at 6:36 PM | marketbeat.com1,832,007 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Bought by Assenagon Asset Management S.A.Assenagon Asset Management S.A. purchased a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,832,007 shares of the company's stock, vaJanuary 17 at 4:09 AM | marketbeat.com10x Genomics (NASDAQ:TXG) Stock Price Down 4.9% - Here's Why10x Genomics (NASDAQ:TXG) Trading Down 4.9% - Time to Sell?January 16, 2025 | marketbeat.comThe Analyst Verdict: 10x Genomics In The Eyes Of 6 ExpertsJanuary 16, 2025 | benzinga.comMirador Capital Partners LP Acquires 22,792 Shares of 10x Genomics, Inc. (NASDAQ:TXG)Mirador Capital Partners LP boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 39.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 80,983 shares of the company's stock after buying an addiJanuary 16, 2025 | marketbeat.com10x Genomics: Strong Revenue Recovery and Promising Growth Opportunities Support Buy RatingJanuary 15, 2025 | markets.businessinsider.com10x Genomics, Inc. (NASDAQ:TXG) Stock Position Raised by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 355.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 355,488 shares of the company's stock after acquiring an additiJanuary 15, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Price Target Lowered to $28.00 at Morgan StanleyJanuary 14, 2025 | americanbankingnews.comBalanced Outlook on 10x Genomics: Strong Q4 Performance Amidst Cautionary SignalsJanuary 14, 2025 | markets.businessinsider.comBarclays Releases a Buy Rating on 10x Genomics (TXG)January 13, 2025 | markets.businessinsider.com10x Genomics (NASDAQ:TXG) Shares Gap Up - Time to Buy?10x Genomics (NASDAQ:TXG) Shares Gap Up - Time to Buy?January 13, 2025 | marketbeat.com10x Genomics (NASDAQ:TXG) Price Target Cut to $28.00 by Analysts at Morgan StanleyMorgan Stanley cut their price target on shares of 10x Genomics from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Monday.January 13, 2025 | marketbeat.com10X Genomics shares rise on Q4 sales beatJanuary 13, 2025 | in.investing.com10x Genomics: Strong Financial Performance and Growth Potential Drive Buy RatingJanuary 13, 2025 | markets.businessinsider.comDiversified Trust Co Invests $511,000 in 10x Genomics, Inc. (NASDAQ:TXG)Diversified Trust Co acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 35,602 shares of the company's stock, valued at approximately $511,000. A numbJanuary 11, 2025 | marketbeat.com10x Genomics: Struggling Amid Operational ChallengesJanuary 6, 2025 | seekingalpha.com10x Genomics (NASDAQ:TXG) Trading Up 11.6% - What's Next?10x Genomics (NASDAQ:TXG) Stock Price Up 11.6% - Here's WhyJanuary 3, 2025 | marketbeat.comCathie Wood’s ARK Investment buys 25K shares of 10x Genomics todayJanuary 3, 2025 | msn.com10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | prnewswire.comCathie Wood’s ARK Investment buys 78K shares of 10x Genomics todayDecember 31, 2024 | markets.businessinsider.com10x Genomics, Inc. (NASDAQ:TXG) Receives Consensus Rating of "Moderate Buy" from Analysts10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) has been given an average rating of "Moderate Buy" by the seventeen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold reDecember 31, 2024 | marketbeat.comGeode Capital Management LLC Has $41.01 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG)Geode Capital Management LLC raised its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,815,710 shares of the company's stock after buying an additionalDecember 25, 2024 | marketbeat.comBruker to Seek Injunction, Appeal After Court Sides with 10x Genomics in Patent DisputeDecember 24, 2024 | marketwatch.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtDecember 24, 2024 | fool.comCathie Wood’s ARK Investment buys 36K shares of 10x Genomics todayDecember 24, 2024 | markets.businessinsider.com10x Genomics secures permanent injunction in Bruker patent infringement lawsuitDecember 23, 2024 | markets.businessinsider.comU.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx ProductsDecember 23, 2024 | prnewswire.com10x Genomics (NASDAQ:TXG) Stock Price Up 4.3% - Should You Buy?10x Genomics (NASDAQ:TXG) Stock Price Up 4.3% - Time to Buy?December 23, 2024 | marketbeat.comState Street Corp Has $39.53 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)State Street Corp increased its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 7.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,750,643 shares of the company's stock after purchasing anDecember 21, 2024 | marketbeat.comBarclays PLC Has $13.61 Million Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)Barclays PLC lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 11.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 602,536 shares of the company's stock after purchasing an aDecember 16, 2024 | marketbeat.comXTX Topco Ltd Purchases 31,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG)XTX Topco Ltd grew its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 241.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 45,008 shares of the company's stock after purchasing an additional 31,8December 11, 2024 | marketbeat.com46,029 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Weiss Asset Management LPWeiss Asset Management LP bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 46,029 shares of the company's stock, valued at appDecember 9, 2024 | marketbeat.comQuantinno Capital Management LP Grows Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)Quantinno Capital Management LP raised its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 380.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 235,026 shares of the company's stock afteDecember 8, 2024 | marketbeat.com10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. decreased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 32.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 651,582 shares of the comDecember 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Makes New $27.78 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)Point72 Asset Management L.P. purchased a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,230,189 shares of the company's stoDecember 6, 2024 | marketbeat.comBenjamin Edwards Inc. Purchases 57,948 Shares of 10x Genomics, Inc. (NASDAQ:TXG)Benjamin Edwards Inc. increased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 18,454.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,262 shares of the company's stock afterDecember 6, 2024 | marketbeat.com10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of 10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seventeen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold rDecember 6, 2024 | marketbeat.comCinctive Capital Management LP Buys New Stake in 10x Genomics, Inc. (NASDAQ:TXG)Cinctive Capital Management LP purchased a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 162,585 shares of the companyDecember 3, 2024 | marketbeat.comFmr LLC Buys 357,470 Shares of 10x Genomics, Inc. (NASDAQ:TXG)Fmr LLC grew its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 2.7% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 13,367,979 shares of the company's stock after acquiring an additional 357,470 shares during the quarter. FDecember 1, 2024 | marketbeat.com10x Genomics, Inc. (NASDAQ:TXG) Shares Purchased by Algert Global LLCAlgert Global LLC boosted its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 214.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 370,958 shares of the company's stock after acquirNovember 24, 2024 | marketbeat.comPrimecap Management Co. CA Purchases 108,600 Shares of 10x Genomics, Inc. (NASDAQ:TXG)Primecap Management Co. CA increased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 58.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 295,400 shares of the company's stock after acquiring an adNovember 23, 2024 | marketbeat.comCIBC Asset Management Inc Sells 79,321 Shares of 10x Genomics, Inc. (NASDAQ:TXG)CIBC Asset Management Inc lowered its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 83.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,938 shares of the company's stock after selling 79,321 shares during the period. CINovember 22, 2024 | marketbeat.com10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Brown Capital Management LLCBrown Capital Management LLC cut its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 11.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,195,319 shares of the company's stock after seNovember 21, 2024 | marketbeat.com10x Genomics and Beckman Coulter Life Sciences Launch New Solution to Automate Single Cell Assay WorkflowsNovember 20, 2024 | msn.com10x Genomics, Inc. (TXG): Among the Best Genomics Stocks to Buy Right NowNovember 20, 2024 | msn.comLMR Partners LLP Invests $1.59 Million in 10x Genomics, Inc. (NASDAQ:TXG)LMR Partners LLP acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 70,303 shares of the company's stock, valued at apprNovember 19, 2024 | marketbeat.com10x Genomics (NASDAQ:TXG) Hits New 52-Week Low - What's Next?10x Genomics (NASDAQ:TXG) Reaches New 1-Year Low - Here's WhyNovember 15, 2024 | marketbeat.comBaillie Gifford & Co. Reduces Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)Baillie Gifford & Co. reduced its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 98.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,378 shares of the company's stock after selling 2,701,775 shares duNovember 14, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Has $143.91 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG)Sumitomo Mitsui Trust Group Inc. lifted its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 3.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,373,212 shares of the company's stock aftNovember 13, 2024 | marketbeat.com Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address TXG Media Mentions By Week TXG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TXG News Sentiment▼0.500.44▲Average Medical News Sentiment TXG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TXG Articles This Week▼126▲TXG Articles Average Week Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nova News Vontier News Camtek News Sensata Technologies News Mirion Technologies News Transcat News Cytek Biosciences News Standard BioTools News EyePoint Pharmaceuticals News Senseonics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TXG) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
